# Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer

> **NCT05257512** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shouyao Holdings (Beijing) Co. LTD** · enrollment: 150 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** SY-3505

## Key facts

- **NCT ID:** NCT05257512
- **Lead sponsor:** Shouyao Holdings (Beijing) Co. LTD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-26
- **Primary completion:** 2024-04-26
- **Final completion:** 2024-08-26
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2023-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05257512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05257512, "Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05257512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*